Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

enVVeno Medical Corporation NVNO

Healthcare  —  Medical Devices
8.67 (0.42) (4.62%) as of 25 Sep
Market cap
$6.3M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

enVVeno Medical Corporation (NVNO) Business Profile

Updated before January 2025

Company Overview

enVVeno Medical Corporation (NASDAQ: NVNO) is a cutting-edge medical technology company specializing in the development of innovative solutions for the treatment of venous diseases. Founded in 2010 and headquartered in Irvine, California, enVVeno focuses on addressing unmet medical needs in the vascular health sector. The company is led by a team of seasoned professionals, including CEO Robert Berman, who brings extensive experience in the healthcare and medical device industries. enVVeno’s mission is to improve the quality of life for patients suffering from chronic venous insufficiency (CVI) and other venous disorders through groundbreaking medical technologies.

Core Business Segments

Venous Valve Technology

The core focus of enVVeno Medical Corporation lies in its proprietary venous valve technology. The company has developed the VenoValve®, a first-of-its-kind implantable device designed to treat severe cases of chronic venous insufficiency (CVI) in the deep veins of the leg. CVI is a debilitating condition that affects millions of people worldwide, leading to symptoms such as leg swelling, pain, and venous ulcers. The VenoValve® aims to restore proper blood flow by mimicking the function of a healthy venous valve, thereby addressing the root cause of the condition.

Research and Development (R&D)

In addition to its flagship product, enVVeno invests heavily in research and development to expand its portfolio of innovative medical devices. The company is exploring new applications for its venous valve technology and is committed to advancing the field of vascular health through continuous innovation.

Business Model

enVVeno Medical Corporation operates on a business model that integrates product development, clinical research, and commercialization. The company generates revenue primarily through the sale of its medical devices, with a focus on the U.S. and international markets. enVVeno collaborates with leading healthcare providers, vascular surgeons, and medical institutions to ensure the successful adoption of its products. The company also invests in clinical trials and regulatory approvals to bring its innovations to market and maintain a competitive edge.

Strategic Direction

Growth in Venous Health Solutions

enVVeno aims to solidify its position as a leader in the venous health sector by expanding the adoption of the VenoValve® and developing new products to address additional venous disorders. The company is focused on scaling its operations and increasing its market share in the U.S. and globally.

Sustainability Goals

As part of its commitment to sustainability, enVVeno is exploring ways to minimize the environmental impact of its manufacturing processes and supply chain. The company is also dedicated to improving patient outcomes and reducing the overall healthcare burden associated with venous diseases.

New Product Categories

In the long term, enVVeno plans to diversify its product portfolio by leveraging its expertise in vascular health. Potential areas of expansion include the development of minimally invasive treatments and diagnostic tools for venous disorders.

Competitive Landscape

enVVeno Medical Corporation operates in a competitive market that includes both established players and emerging companies in the medical device industry. Key competitors include:

  • Medtronic: A global leader in medical technology, offering a wide range of vascular health solutions.
  • Boston Scientific: Known for its innovative cardiovascular and peripheral vascular devices.
  • Cook Medical: Specializes in minimally invasive medical devices, including venous stents and other vascular products.
  • Veniti (acquired by Boston Scientific): Focused on venous stent technology for the treatment of venous diseases.

Despite the competition, enVVeno differentiates itself through its unique focus on venous valve technology and its commitment to addressing unmet medical needs.

Risk Factors

Market Dependence

enVVeno’s success is heavily dependent on the adoption of the VenoValve® and the overall demand for venous health solutions. Any delays in regulatory approvals or challenges in market adoption could impact the company’s revenue and growth prospects.

Supply Chain Disruptions

Like many medical device companies, enVVeno faces risks related to supply chain disruptions, which could affect the production and delivery of its products.

Regulatory and Clinical Risks

The medical device industry is highly regulated, and enVVeno must navigate complex regulatory requirements to bring its products to market. Additionally, the success of its products depends on the outcomes of clinical trials, which carry inherent risks.

Recent Developments

Clinical Trials

enVVeno has made significant progress in clinical trials for the VenoValve®, with promising results that demonstrate its safety and efficacy. The company is currently working towards obtaining FDA approval for the device.

Strategic Partnerships

To accelerate its growth, enVVeno has entered into strategic partnerships with leading healthcare providers and research institutions. These collaborations aim to advance the development and adoption of its venous health solutions.

Global Developments

The COVID-19 pandemic has highlighted the importance of healthcare innovation, and enVVeno has adapted to the changing landscape by prioritizing digital engagement with healthcare professionals and patients.

Investment Considerations

Strengths

  • Innovative Technology: enVVeno’s proprietary venous valve technology addresses a significant unmet medical need.
  • Experienced Leadership: The company’s management team has a proven track record in the healthcare industry.
  • Growth Potential: With a focus on expanding its product portfolio and market presence, enVVeno is well-positioned for long-term growth.

Risks

  • Regulatory Challenges: Delays in obtaining FDA approval or meeting regulatory requirements could impact the company’s timeline for commercialization.
  • Market Competition: enVVeno faces competition from established players in the medical device industry.
  • Financial Risks: As a growth-stage company, enVVeno may require additional funding to support its operations and R&D efforts.

Conclusion

enVVeno Medical Corporation is a pioneering company in the field of venous health, with a strong focus on innovation and improving patient outcomes. While the company faces challenges related to regulatory approvals and market competition, its unique technology and strategic direction position it for success in the growing vascular health market. With a commitment to sustainability and continuous innovation, enVVeno is poised to make a significant impact on the lives of patients worldwide and deliver value to its stakeholders.